Charles A. McWherter
2022
In 2022, Charles A. McWherter earned a total compensation of $1.2M as President of R&D at Cymabay Therapeutics, a 8% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $240,000 |
|---|---|
| Option Awards | $525,465 |
| Salary | $456,685 |
| Other | $3,963 |
| Total | $1,226,113 |
McWherter received $525.5K in option awards, accounting for 43% of the total pay in 2022.
McWherter also received $240K in non-equity incentive plan, $456.7K in salary and $4K in other compensation.
Rankings
In 2022, Charles A. McWherter's compensation ranked 2,633rd out of 5,753 executives tracked by ExecPay. In other words, McWherter earned more than 54.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,633 out of 5,753 | 54th |
Division Manufacturing | 1,461 out of 3,133 | 53rd |
Major group Chemicals And Allied Products | 667 out of 1,419 | 53rd |
Industry group Drugs | 620 out of 1,320 | 53rd |
Industry Pharmaceutical Preparations | 447 out of 966 | 54th |
Source: SEC filing on April 19, 2023.
McWherter's colleagues
We found two more compensation records of executives who worked with Charles A. McWherter at Cymabay Therapeutics in 2022.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019